Lakhwani Prerna, Agarwal Priya, Goel Ashish, Nayar Nidhi, Pande Pankaj, Kumar Kapil
Gynae Oncology, BL Kapur Super Specialty Hospital, Pusa Road, Delhi, India.
Surgical oncology, BL Kapur Super Specialty Hospital, Pusa Road, Delhi, India.
Indian J Surg Oncol. 2019 Dec;10(4):662-667. doi: 10.1007/s13193-019-00970-1. Epub 2019 Aug 21.
High-grade endometrial carcinomas are a heterogeneous group of clinically aggressive tumours. They include FIGO grade 3 endometrioid adenocarcinoma, uterine papillary serous carcinoma (UPSC), clear cell carcinoma, undifferentiated carcinoma and carcinosarcomas or malignant mixed Mullerian tumour (MMMT). The aim of this study is to look at clinicopathological features and survival outcomes of high-grade endometrial cancers of the uterus in our centre. A tertiary care centre in India. The study design is retrospective with survival analysis. We did a retrospective analysis of all patients admitted with a diagnosis of high-grade uterine carcinoma. Data regarding baseline characteristics, disease profiles, surgical outcomes, complications, extent of surgical staging, duration of surgery, blood loss, length of hospital stay, drain output, wound infection, surgico-pathological stage and grade, tumour size and location, myometrium and lymphovascular invasion, node positivity, adjuvant treatment, overall survival and recurrence-free survival. Survival analysis was done using the Kaplan-Meier method. We had 115 females diagnosed with endometrial cancer. Of these, 40 patients had high-grade endometrial cancer. Mean age at presentation was 64.7 years (range 33-80 years). Of this, endometrioid adenocarcinoma grade III was the commonest (37.5%), followed by UPSC in 32.5% and MMMT in 22.5% patients. Clear cell variant and mixed dedifferentiated variant were reported in 5% and 2.5%, respectively. Over 48 months of follow-up, recurrence was detected in eight patients (20%) and median time to recurrence was 11 months. Mean recurrence-free survival was 32.8 months and mean overall survival was 38.6 months High-grade endometrial cancers are aggressive tumours of postmenopausal women. Surgical staging and combination chemotherapy along with radiation therapy are the mainstay of treatment. In spite of adequate debulking followed by adjuvant therapy, survival remains poor.
高级别子宫内膜癌是一组临床侵袭性肿瘤的异质性群体。它们包括国际妇产科联盟(FIGO)3级子宫内膜样腺癌、子宫乳头状浆液性癌(UPSC)、透明细胞癌、未分化癌以及癌肉瘤或恶性米勒管混合瘤(MMMT)。本研究的目的是观察我们中心子宫高级别子宫内膜癌的临床病理特征和生存结局。这是印度的一家三级医疗中心。研究设计为回顾性生存分析。我们对所有诊断为高级别子宫癌的患者进行了回顾性分析。收集了有关基线特征、疾病概况、手术结果、并发症、手术分期范围、手术时长、失血量、住院时间、引流量、伤口感染、手术病理分期和分级、肿瘤大小和位置、肌层和淋巴管浸润、淋巴结阳性情况、辅助治疗、总生存期和无复发生存期的数据。使用Kaplan-Meier方法进行生存分析。我们共诊断出115例子宫内膜癌女性患者。其中,40例患有高级别子宫内膜癌。就诊时的平均年龄为64.7岁(范围33 - 80岁)。其中,III级子宫内膜样腺癌最为常见(37.5%),其次是UPSC(32.5%)和MMMT(22.5%)。透明细胞变异型和混合去分化变异型分别占5%和2.5%。在超过48个月的随访中,8例患者(20%)出现复发,复发的中位时间为11个月。平均无复发生存期为32.8个月,平均总生存期为38.6个月。高级别子宫内膜癌是绝经后女性的侵袭性肿瘤。手术分期、联合化疗以及放疗是主要的治疗方法。尽管进行了充分的肿瘤减灭术并辅以辅助治疗,但生存率仍然较低。